Basilea Pharmaceutica AG saw its shares rise sharply after releasing first-half 2026 results that beat market expectations and announcing a substantial improvement to its full-year targets.
Shares moved up 6.1% to close at CHF 57.5 following the update, with intraday trading reaching a high of CHF 58.6 as investors reacted to the company-specific news. The stock approached its 52-week high of CHF 59.2 during the session.
Financial performance
For the first half of 2026 Basilea posted revenue of CHF 119 million, an increase of 14% versus the same period a year earlier. Management attributed the gain to continued strong global demand for Cresemba, the company’s primary antifungal product used to treat invasive infections.
Profitability showed notable improvement. Net profit for the period rose 77% to CHF 30 million. Operating profit increased by roughly 32% to CHF 32 million, a result that exceeded expectations across key metrics.
Upgraded outlook
Management also raised its guidance for 2026, increasing its full-year revenue growth objective to approximately 15% from a prior forecast of around 10%. The company more than doubled its operating profit growth outlook, now targeting approximately 40% growth compared with the earlier projection of about 20%.
Alongside the financial upgrades, Basilea confirmed that the Phase 3 program for fosmanogepix - a broad-spectrum antifungal candidate in late-stage development - remains on track. Management presented this as further evidence of near-term commercial potential within the company’s pipeline.
Market context
The broader market provided little assistance on the day, with U.S. indices trading lower. Despite a negative macro environment, the company-specific earnings beat and the substantial upward revision to operating profit expectations were sufficient to propel the stock toward multi-month highs.
Within the Swiss pharmaceutical sector there were no comparable, company-level catalysts reported on the same day, leaving Basilea’s performance as a distinctly stock-specific move.
Outlook implications
Investors interpreted the combination of a clean earnings beat, an upgraded profit outlook, and confirmed progress in the fosmanogepix program as a justification for re-evaluating the company’s valuation. With shares trading near recent highs and analyst consensus price targets reportedly well above current levels, the results appear to have reinforced a bullish view on Basilea's commercial trajectory for the remainder of 2026.